Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling

De-Xing Hou1, Takuma Kumamoto

  • 1The United Graduate School of Agricultural Sciences, Faculty of Agriculture, Kagoshima University, Kagoshima City, Japan.

Insights

Flavonoids inhibit protein kinases, crucial in cancer development, acting as targeted chemoprevention agents. This research reveals their direct binding to kinases, offering new avenues for natural compound-based cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinases regulate vital cell signaling pathways and functions.
  • Dysregulated protein kinase activity is linked to cancer development.
  • Targeting protein kinases is a key strategy for cancer chemoprevention and therapy.

Purpose of the Study:

  • To review the interactions between flavonoids and protein kinases.
  • To highlight direct binding and molecular modeling of flavonoid-kinase interactions.
  • To explore flavonoids as novel protein kinase inhibitors for cancer chemoprevention.

Main Methods:

  • Literature review of flavonoid-protein kinase interactions.
  • Analysis of studies on direct binding of flavonoids to kinases (e.g., Akt/PKB, JAK1, MEK1, PI3K, MKK4, Raf1, ZAP-70).
  • Examination of molecular modeling data regarding these interactions.

Main Results:

  • Flavonoids directly bind to specific protein kinases, altering their phosphorylation states.
  • Flavonoids modulate cell signaling pathways involved in carcinogenesis.
  • Evidence suggests flavonoids act as protein kinase inhibitors, not just antioxidants.

Conclusions:

  • Flavonoids show potential as natural, compound-based protein kinase inhibitors for cancer chemoprevention.
  • Molecular modeling provides insights for designing novel flavonoid-derived kinase inhibitors.
  • This research reframes the role of flavonoids in cancer therapy beyond antioxidant properties.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...